Danny Hsu: The Diagnostic Challenge of Pulmonary Embolism During Pregnancy
Danny Hsu, President of THANZ, shared RPTH Journal’s post on LinkedIn, adding:
“Excellent article on the challenging scenario of diagnosing PE in pregnancy!”
RPTH Journal shared a post on LinkedIn, about a recent article by Fanny Collange et al, adding: :
“Diagnosing pulmonary embolism in pregnancy is still harder than we think.
We rely heavily on clinical probability scores like Wells and Geneva, but do they actually work in pregnant women with prior VTE?
A new Highlow ancillary study puts this to the test in 1,110 high-risk pregnancies.
The results are eye-opening
Among 102 suspected PE cases:
- Only 12 were confirmed
- Incidence during pregnancy: 2.6% of suspected cases
- Postpartum: 42% of suspected cases
Now the key finding:
Wells, Geneva, and pregnancy-adapted Geneva scores all showed modest discriminatory power
Translation:
These tools struggle in the exact population where we need them most.
Why?
Because pregnancy changes physiology, symptoms overlap with normal pregnancy, and prior VTE history dominates risk assessment.
Big takeaway:
We urgently need pregnancy-specific PE decision tools to safely reduce imaging and radiation exposure.
This study highlights a major unmet need in maternal thrombosis care.”
Title: Assessment of clinical probability scores for pulmonary embolism diagnosis during pregnancy and postpartum in women with a history of venous thromboembolism: a Highlow ancillary study
Authors: Fanny Collange, Ingrid M Bistervels, Andrea Buchmuller, Hanke MG Wiegers, Fionnuala Ní Áinle, Peter Verhamme, Anne F Jacobsen, Anette T Hansen, Marc A Rodger, Maria T DeSancho, Roman G Shmakov, Luuk JJ Scheres, Celine Chauleur, Saskia Middeldorp, Bernard Tardy
Read the Full Article on RPTH Journal.
Find more posts featuring Danny Hsu on Hemostasis Today.
-
Jul 4, 2026, 17:38Michael Stark: Greater Improvements in Cerebral Oxygenation With Restrictive Transfusion Thresholds
-
Jul 4, 2026, 17:27Reza Shojaei: How America Won the Plasma Race
-
Jul 4, 2026, 17:26Akshat Jain: The First CRISPR-Cas9 Gene Therapy Approved for Children as Young as 2 with SCD
-
Jul 4, 2026, 17:25Francesca Palandri: Dynamic, Treatment Response-Driven Risk Assessment in Polycythemia Vera
-
Jul 4, 2026, 17:24Thierry Burnouf: The Fragile Supply of Human Hyperimmune Immunoglobulins
-
Jul 4, 2026, 15:41Emmanuel J. Favaloro: New Research Highlights Benchmarks for Low Molecular Weight Heparin Monitoring
-
Jul 4, 2026, 15:38Roshni Kulkarni: Maternal Mortality In Bleeding Disorders
-
Jul 4, 2026, 15:34Alejandro González Veliz: Does Elevated Lp(a) Always Mean the Same Cardiovascular Risk?
-
Jul 4, 2026, 15:20Bruno Pougault: Heparin Monitoring Remains One of the Most Challenging Areas in Laboratory Hemostasis